Capivasertib (BioDeep_00000176365)
human metabolite blood metabolite
代谢物信息卡片
4-amino-N-[1-(4-chlorophenyl)-3-hydroxypropyl]-1-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperidine-4-carboxamide
化学式: C21H25ClN6O2 (428.17274199999997)
中文名称:
谱图信息:
最多检出来源 Rattus norvegicus(blood) 80%
分子结构信息
SMILES: C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4
InChI: InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)
描述信息
同义名列表
4 个代谢物同义名
4-amino-N-[1-(4-chlorophenyl)-3-hydroxypropyl]-1-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperidine-4-carboxamide; 4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide; 4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo(2,3-D)pyrimidin-4-yl)piperidine-4-carboxamide; Capivasertib
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Parham Jabbarzadeh Kaboli, Shuang Luo, Yao Chen, Masume Jomhori, Saber Imani, Shixin Xiang, Zhigui Wu, Mingxing Li, Jing Shen, Yueshui Zhao, Xu Wu, Chi Hin Cho, Zhangang Xiao. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
Gene.
2022 Mar; 816(?):146171. doi:
10.1016/j.gene.2021.146171. [PMID: 35026293] - Xufen Yu, Jia Xu, Yudao Shen, Kaitlyn M Cahuzac, Kwang-Su Park, Brandon Dale, Jing Liu, Ramon E Parsons, Jian Jin. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
Journal of medicinal chemistry.
2022 02; 65(4):3644-3666. doi:
10.1021/acs.jmedchem.1c02165. [PMID: 35119851] - Veronika Voronova, Marie Cullberg, Philip Delff, Joanna Parkinson, Corina Dota, Gaia Schiavon, Brijesh Maroj, Dinko Rekić, S Y Amy Cheung. Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.
British journal of clinical pharmacology.
2022 02; 88(2):858-864. doi:
10.1111/bcp.15006. [PMID: 34309049] - Fang Sun, Chenglin Mu, Hang Fai Kwok, Jiyuan Xu, Yingliang Wu, Wanhong Liu, Jean-Marc Sabatier, Cédric Annweiler, Xugang Li, Zhijian Cao, Yingqiu Xie. Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.
International journal of biological sciences.
2021; 17(9):2348-2355. doi:
10.7150/ijbs.57810. [PMID: 34239361] - Zhe Zhang, Li Nong, Meng-Lei Chen, Ming-Hui Liu, Wen-Wu Cheng. A validated LC-MS/MS method for the quantification of capivasertib in dog plasma: Application to its pharmacokinetics study.
Biomedical chromatography : BMC.
2020 Oct; 34(10):e4920. doi:
10.1002/bmc.4920. [PMID: 32537750] - Lillian M Smyth, Kenji Tamura, Mafalda Oliveira, Eva M Ciruelos, Ingrid A Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J Ambrose, Jack Ashton, Alan Barnicle, Des D Cashell, Claire Corcoran, Elza C de Bruin, Andrew Foxley, Joana Hauser, Justin P O Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S Taylor, Sarat Chandarlapaty, José Baselga, David M Hyman. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 08; 26(15):3947-3957. doi:
10.1158/1078-0432.ccr-19-3953. [PMID: 32312891] - M P Kolinsky, P Rescigno, D Bianchini, Z Zafeiriou, N Mehra, J Mateo, V Michalarea, R Riisnaes, M Crespo, I Figueiredo, S Miranda, D Nava Rodrigues, P Flohr, N Tunariu, U Banerji, R Ruddle, A Sharp, J Welti, M Lambros, S Carreira, F I Raynaud, K E Swales, S Plymate, J Luo, H Tovey, N Porta, R Slade, L Leonard, E Hall, J S de Bono. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020 05; 31(5):619-625. doi:
10.1016/j.annonc.2020.01.074. [PMID: 32205016] - Robert H Jones, Angela Casbard, Margherita Carucci, Catrin Cox, Rachel Butler, Fouad Alchami, Tracie-Ann Madden, Catherine Bale, Pavel Bezecny, Johnathan Joffe, Sarah Moon, Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Andrew Foxley, Sacha J Howell. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
The Lancet. Oncology.
2020 03; 21(3):345-357. doi:
10.1016/s1470-2045(19)30817-4. [PMID: 32035020] - S Hrebien, V Citi, I Garcia-Murillas, R Cutts, K Fenwick, I Kozarewa, R McEwen, J Ratnayake, R Maudsley, T H Carr, E C de Bruin, G Schiavon, M Oliveira, N Turner. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
Annals of oncology : official journal of the European Society for Medical Oncology.
2019 06; 30(6):945-952. doi:
10.1093/annonc/mdz085. [PMID: 30860573] - Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, Gerald Batist, Philippe L Bedard, Benoit You, Shannon N Westin, Peter Kabos, Michelle D Garrett, Mathew Tall, Helen Ambrose, J Carl Barrett, T Hedley Carr, S Y Amy Cheung, Claire Corcoran, Marie Cullberg, Barry R Davies, Elza C de Bruin, Paul Elvin, Andrew Foxley, Peter Lawrence, Justin P O Lindemann, Rhiannon Maudsley, Martin Pass, Vicky Rowlands, Paul Rugman, Gaia Schiavon, James Yates, Jan H M Schellens. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018 05; 24(9):2050-2059. doi:
10.1158/1078-0432.ccr-17-2260. [PMID: 29066505] - Masayuki Yamaji, Akinobu Ota, Md Wahiduzzaman, Sivasundaram Karnan, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Yoshitaka Hosokawa, Masayuki Haniuda. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Cancer medicine.
2017 Nov; 6(11):2646-2659. doi:
10.1002/cam4.1179. [PMID: 28960945] - David M Hyman, Lillian M Smyth, Mark T A Donoghue, Shannon N Westin, Philippe L Bedard, Emma J Dean, Hideaki Bando, Anthony B El-Khoueiry, José A Pérez-Fidalgo, Alain Mita, Jan H M Schellens, Matthew T Chang, Jonathan B Reichel, Nancy Bouvier, S Duygu Selcuklu, Tara E Soumerai, Jean Torrisi, Joseph P Erinjeri, Helen Ambrose, J Carl Barrett, Brian Dougherty, Andrew Foxley, Justin P O Lindemann, Robert McEwen, Martin Pass, Gaia Schiavon, Michael F Berger, Sarat Chandarlapaty, David B Solit, Udai Banerji, José Baselga, Barry S Taylor. AKT Inhibition in Solid Tumors With AKT1 Mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2017 Jul; 35(20):2251-2259. doi:
10.1200/jco.2017.73.0143. [PMID: 28489509] - Rute B Marques, Ashraf Aghai, Corrina M A de Ridder, Debra Stuurman, Sander Hoeben, Agnes Boer, Rebecca P Ellston, Simon T Barry, Barry R Davies, Jan Trapman, Wytske M van Weerden. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
European urology.
2015 Jun; 67(6):1177-1185. doi:
10.1016/j.eururo.2014.08.053. [PMID: 25220373] - Paul Toren, Soojin Kim, Thomas Cordonnier, Claire Crafter, Barry R Davies, Ladan Fazli, Martin E Gleave, Amina Zoubeidi. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
European urology.
2015 Jun; 67(6):986-990. doi:
10.1016/j.eururo.2014.08.006. [PMID: 25151012] - Fan Zhang, Masafumi Kumano, Eliana Beraldi, Ladan Fazli, Caigan Du, Susan Moore, Poul Sorensen, Amina Zoubeidi, Martin E Gleave. Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival.
Nature communications.
2014 Dec; 5(?):5775. doi:
10.1038/ncomms6775. [PMID: 25503391] - Barry R Davies, Hannah Greenwood, Phillippa Dudley, Claire Crafter, De-Hua Yu, Jingchuan Zhang, Jing Li, Beirong Gao, Qunsheng Ji, Juliana Maynard, Sally-Ann Ricketts, Darren Cross, Sabina Cosulich, Christine C Chresta, Ken Page, James Yates, Clare Lane, Rebecca Watson, Richard Luke, Donald Ogilvie, Martin Pass. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Molecular cancer therapeutics.
2012 Apr; 11(4):873-87. doi:
10.1158/1535-7163.mct-11-0824-t. [PMID: 22294718]